Professor Ian Peake BSc PhD FRCPath

Emeritus Professor of Molecular Medicine

Department of Infection, Immunity & Cardiovascular DiseaseIan Peake
University of Sheffield
Medical School
Beech Hill Road
Sheffield
S10 2RX
Telephone: 44 (0) 7785 247 928
Fax: 44 (0)114 271 1863
Email: i.r.peake@sheffield.ac.uk

Biography:

I joined the University in 1990 as the Sir Edward Mellanby Professor of Molecular Medicine and also hold an Honorary Consultant position with the Sheffield Teaching Hospitals NHS Foundation Trust. I have been Deputy Director of the Division of Genomic Medicine and Director of Research for Medicine.

I am currently focused on my research into inherited bleeding disorders in particular von Willebrands disease.

Research Interests:

My research interests are inherited disorders of Haemostasis and Thrombosis.

Teaching Interests:

I teach at the postgraduate level.

Professional Activities:

I was a partner of the Health and Care Professions Council (HCPC) as a Clinical Scientist, I was also Registration Assessor for HCPC and for the Association of Clinical Scientists.

I am a past President of the International Society on Thrombosis and Haemostasis (ISTH Congress Birmingham 2003) and Chair of the ISTH Council (2006-2008). I am a past Council member of the British Society for Haemostasis and Thrombosis and the European Association for Haemophilia and Allied Disorders. I was also a member of the Education Committee of the European Haematology Association until 2012.

Current Projects:

My current research interests focus on von Willebrands Disease. I was a co-applicant on an NIH funded PPG (the Zimmerman Project) with collaborators in Canada and USA. I also co-chaired the EU von Willebrands disease collaborative group which has projects continuing from the EU funded MCMDM-1VWD project which I directed.

Key Publications:

  1. Cartwright A, Peake IR, Goodeve AC, Hampshire DJ. In silico analysis highlights the copy number variation mechanism responsible for the historically reported VWF exon 42 deletion. Haemophilia. 2016 Sep;22(5):e484-7.

  2. Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood. 2016 May 19;127(20):2481-8.

  3. Hampshire DJ, Abuzenadah AM, Cartwright A, Al-Shammari NS, Coyle RE, Eckert M, Al-Buhairan AM, Messenger SL, Budde U, Gürsel T, Ingerslev J, Peake IR, Goodeve AC. Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thromb Haemost. 2013 Aug;110(2):264-74.

  4. Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013 May;98(5):667-74.

  5. Eikenboom J, Federici AB, Dirven RJ, Castaman G, Rodeghiero F, Budde U, Schneppenheim R, Batlle J, Canciani MT, Goudemand J, Peake I, Goodeve A; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood. 2013 Mar 21;121(12):2336-9.

  6. Hickson N, Hampshire D, Winship P, Goudemand J, Schneppenheim R, Budde U, Castaman G, Rodeghiero F, Federici AB, James P, Peake I, Eikenboom J, Goodeve A. von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.; on behalf of the MCMDM-1VWD and ZPMCB-VWD study groups. J Thromb Haemost. 2010 May 21.

  7. Peake IR, Goodeve AC. Genetic testing for von Willebrand disease: the case for. J Thromb Haemost. 2010 Jan;8(1):13-6.

  8. Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Pérez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost. 2008 May;6(5):762-71.

  9. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, Batlle J, Meyer D, Mazurier C, Fressinaud E, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Pasi J, Hill F, Peake I, Rodeghiero FResponse to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008 Apr 1;111(7):3531-9.

  10. Peake I, Goodeve A.Type 1 von Willebrand disease. J Thromb Haemost. 2007 Jul;5 Suppl 1:7-11.

  11. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L, Hallden C, Guilliatt A, Lester W, Peake Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). I. Blood. 2007 Jan 1;109(1):112-21.

  12. Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost. 2006 Apr;4(4):774-82.

  13. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006 Apr;4(4):766-73.

Search PubMed:   



PubMed Logo